Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-25. ← Back to Evidence Library

title: "Exenatide: What the evidence says" slug: exenatide status: Draft (v1), pending review by Dr. Nova Reyes (Batch F #61) last_checked: 2026-10-25 evidence_verdict: "Type 2 diabetes (labeled): Strong · Parkinson's disease: Limited (mixed results) · Gray-market exendin-4: No human data" card_verdict: "Strong (type 2 diabetes) · Parkinson's: mixed results, phase 3 negative · Gray-market vials: No human data" related: [liraglutide, semaglutide, dulaglutide]

Draft (v1), pending review. Not public. · ← Library · DRAFT · not published · last checked 2026-10-25

Exenatide: what the evidence says

At a glance

What it is: a synthetic version of exendin-4, a 39-amino-acid peptide first found in Gila monster saliva, and the first GLP-1 receptor agonist approved in the US: Byetta (twice a day) and Bydureon / Bydureon BCise (extended-release). ^{R1, R2} Gray-market sellers offer "exendin-4" vials.

What the evidence says: it lowers blood sugar in type 2 diabetes. ^{R1, R4} In the 14,752-person EXSCEL trial, the extended-release form was safe for the heart but did not significantly reduce heart attacks, strokes or cardiovascular deaths (HR 0.91, P=0.06 for superiority). ^R5 For Parkinson's disease, a 62-person trial was positive ^R6 but the larger 194-person phase 3 trial found no benefit. ^R7

Biggest risks: pancreatitis (including fatal cases), low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, severe stomach side effects, and immune-mediated low platelets with serious bleeding. ^R1 The extended-release forms (Bydureon, Bydureon BCise) carry a boxed warning for thyroid C-cell tumors in rodents, like other long-acting GLP-1 drugs. ^R7

Rating


Human Human evidence	Strong for type 2 diabetes blood-sugar control ^{R1, R4, R5}; Limited (mixed results) for Parkinson's disease ^{R6, R7}; No human data on gray-market "exendin-4" vials
Animal Animal / lab evidence	Preclinical neuroprotection in Parkinson's models (cited by trial authors, not reviewed here) ^R6
Regulatory	FDA-approved: Byetta NDA 021773, Bydureon NDA 022200, Bydureon BCise NDA 209210; Drugs@FDA lists all three as Discontinued · generic exenatide approved (Amneal ANDA 206697, Nov 19, 2024) ^{R2, R3} · WADA: not named on the 2026 List ^R8
Established human dose	For labeled use: on the FDA label ^R1. Study details lists what trials used

Evidence verdict: Type 2 diabetes (labeled): Strong · Parkinson's disease: Limited (mixed results) · Gray-market exendin-4: No human data Card verdict: Strong (type 2 diabetes) · Parkinson's: mixed results, phase 3 negative · Gray-market vials: No human data Card note: Gray-market "exendin-4" is not the approved product, see page.

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: the diabetes trials were sponsored by the manufacturers (Amylin/Eli Lilly for the 30-week trial ^R4; Amylin/AstraZeneca for EXSCEL ^R5); the Parkinson's trials were academic (Michael J Fox Foundation; NIHR and Cure Parkinson's). ^{R6, R7}

What is it?

Exenatide activates the GLP-1 receptor: it raises insulin when blood sugar is high, lowers glucagon and slows stomach emptying. ^R1 Byetta is injected twice a day; the extended-release forms are injected once a week. ^{R1, R5} Related pages: Liraglutide, Semaglutide, Dulaglutide.

Does it work?

Human Type 2 diabetes (add-on to metformin): 336 patients, 30 weeks: HbA1c fell about 0.8 percentage points on the higher amount vs no change on placebo, with about 3 kg weight loss. ^R4
Human Heart outcomes (EXSCEL): 14,752 people, median 3.2 years: events 11.4% vs 12.2% (HR 0.91, 95% CI 0.83–1.00); non-inferior on safety, not superior. ^R5
Human Parkinson's disease, phase 2: 62 patients, 48 weeks plus washout: motor scores 3.5 points better than placebo. ^R6
Human Parkinson's disease, phase 3 (Exenatide-PD3): 194 patients, 96 weeks: no difference from placebo (p=0.47); authors found "no evidence to support exenatide as a disease-modifying treatment." ^R7

Is it safe?

Human Label warnings (Byetta): acute pancreatitis, low blood sugar with insulin secretagogues or insulin, acute kidney injury from volume loss, severe GI reactions, drug-induced immune thrombocytopenia (serious and sometimes fatal bleeding). No boxed warning on the Byetta label. ^R1
Human EXSCEL: rates of pancreatitis, pancreatic cancer and medullary thyroid carcinoma did not differ from placebo. ^R5
Human Parkinson's trials: injection-site reactions and GI symptoms were common; serious events similar to placebo in phase 3. ^{R6, R7}

Gray-market "research use only" Exenatide: extra risks

Not the approved product. "Research" exendin-4 is not Byetta, Bydureon or the FDA-approved generic; identity, strength and sterility are unknown. Unknown Whether these vials are synthetic exenatide or another exendin variant is unknown.

What we don't know

Unknown Quality of gray-market "exendin-4"
Unknown Whether any subgroup of Parkinson's patients benefits (the phase 3 authors call for further studies)
Unknown US availability now that brand products are listed as Discontinued

Is it legal?

US: FDA-approved for type 2 diabetes (Byetta NDA 021773; Bydureon NDA 022200; Bydureon BCise NDA 209210). Drugs@FDA lists all three brand products as Discontinued; generic exenatide (Amneal, ANDA 206697) was approved Nov 19, 2024. ^{R2, R3} Not approved for Parkinson's disease or weight loss. EU, UK and others: UNVERIFIED. WADA: not named on the 2026 Prohibited List. ^R8

Study details

These are amounts researchers used, not recommendations. ### R4 Human RCT: add-on to metformin (DeFronzo 2005) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | DeFronzo 2005 | 336 randomized adults with type 2 diabetes on metformin (272 completed) | Subcutaneous | 5 or 10 mcg twice daily | 30 weeks | HbA1c −0.78% (10 mcg) and −0.40% (5 mcg) vs +0.08% placebo; weight −2.8 kg (10 mcg) | Mostly mild-moderate GI events; no severe hypoglycemia | [PMID 15855572](https://pubmed.ncbi.nlm.nih.gov/15855572/) | ### R5 Human RCT: EXSCEL cardiovascular outcomes (Holman 2017) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | Holman 2017 | 14,752 people with type 2 diabetes | Subcutaneous | 2 mg once weekly | Median 3.2 years | MACE HR 0.91 (0.83–1.00) | Not superior to placebo | [PMID 28910237](https://pubmed.ncbi.nlm.nih.gov/28910237/) · [NCT01144338](https://clinicaltrials.gov/study/NCT01144338) | ### R6 Human RCT: Parkinson's phase 2 (Athauda 2017) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | Athauda 2017 | 62 adults with moderate Parkinson's | Subcutaneous | 2 mg once weekly | 48 weeks + 12-week washout | MDS-UPDRS III −3.5 points vs placebo | Single centre; small | [PMID 28781108](https://pubmed.ncbi.nlm.nih.gov/28781108/) · [NCT01971242](https://clinicaltrials.gov/study/NCT01971242) | ### R7 Human RCT: Parkinson's phase 3 (Vijiaratnam 2025) | Study | People / model | Route | Amount used | Follow-up | Reported | Side effects / limitations | Citation | |---|---|---|---|---|---|---|---| | Vijiaratnam 2025 | 194 adults with Parkinson's | Subcutaneous | 2 mg once weekly | 96 weeks | No difference (p=0.47) | Null primary result | [PMID 39919773](https://pubmed.ncbi.nlm.nih.gov/39919773/) · [NCT04232969](https://clinicaltrials.gov/study/NCT04232969) |

Full reference list (PubMed, ClinicalTrials.gov, openFDA and DailyMed entries checked Oct 25, 2026)

^R1 DailyMed. BYETTA (exenatide) injection label, AstraZeneca, effective Sep 2, 2025. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f
^R2 FDA. Drugs@FDA data (openFDA drugsfda), exenatide: NDA 021773 (Byetta), NDA 022200 (Bydureon), NDA 209210 (Bydureon BCise), marketing status Discontinued, checked Oct 25, 2026. https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:exenatide · https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773
^R3 FDA. Drugs@FDA, ANDA 206697 (Amneal, exenatide synthetic), original approval 2024-11-19. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206697
^R4 DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005. PMID 15855572
^R5 Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017. PMID 28910237
^R6 Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID 28781108
^R7 Vijiaratnam N, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3 trial. Lancet. 2025. PMID 39919773
^R8 WADA. The 2026 Prohibited List (in force 1 January 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use Exenatide. Talk to a clinician you trust before using any drug, and report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).

Approved for Adam Greene by Dr. Nova Reyes, 2026-10-25.